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With the advent of targeted therapies in the past decade, the
transition from cytotoxic treatments to highly selective mole-
culeshasradicallyalteredandexpandedoptionsforcancerpa-
tients. Myelosuppression, mucositis, nausea, and hair loss are
no longer the inevitable “partners” of antitumor drugs. For the
right patient, a single oral medication may prove more benefi-
cial than combination cytotoxic therapy. The attractiveness of
thisalternativeandrecentsuccessesinearlyclinicaltrialshave
led to high patient interest in access to these new therapies
evenduringphaseItreatment,andthesuccessoftheapproach
promisesto shortenandtransformourlong-establishedpath
of successive steps to drug approval.
Inthepast,phaseItrialswerepursuedtoestablishthe
maximum tolerated dose (MTD), to identify organ tox-
icities that might limit further development, and to pro-
vide hints for the focus of phase II trials. The occasional
responseseeninphaseI,althoughmeaningfulintermsof
establishingthebiologicalactivityofthedrug,oftenmis-
led investigators regarding ultimate paths for approval
[1]. Melanoma, a notoriously unresponsive tumor, often
tantalized investigators with an occasional response to
drugs such as carmustine (BCNU), trabectedin, pacli-
taxel, and others, during phase I studies. This phase I
melanoma experience usually led to a dead end for drug
approval in phase II trials [2].
Several recent phase I trials have disclosed startling ev-
idence that, when patients are appropriately selected, con-
vincing benefit can be realized in the earliest of trials,
settingthestageforrapiddrugapproval.Inarecentissueof
the New England Journal of Medicine, investigators report
dramatic evidence of response in melanoma patients to a
bRAF inhibitor [3], and in a second paper, currently in
press, similar results in non-small cell lung cancer
(NSCLC) patients treated with an inhibitor of anaplastic
lymphomakinase(ALK)[4].Ineachcase,theresponserate
was 50% and the overall benefit rate (partial and com-
plete responses, and minor responses and stable disease for
at least 3 months) approached 90%. Conventional treat-
mentsfortheseindicationsareexpectedtoproducebriefre-
sponses in a minority of patients, and at the cost of severe
toxicity. These findings are all the more impressive in that
many of these patients had received prior conventional
chemo- or immunotherapy, and their tumors, as a histolog-
ical type, were notoriously unresponsive to treatment. Con-
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The Oncologist 2010;15:1023–1025 www.TheOncologist.comfirmatory phase II and phase III trials are ongoing for both
drugs, but the phase I success has created a strong demand
for early access to them. The number of potential patients,
particularly in the case of melanoma, vastly exceeds the
number of available slots on trials. The respective pharma-
ceutical companies and the U.S. Food and Drug Administra-
tion are working diligently to establish compassionate
treatmentprogramsandtoreachearlyapprovalformarketing.
What made the phase I experience so successful? The
answer is simple: patient selection. In each of these trials, a
biomarker for response was obvious. The bRAF inhibitor
designed by Plexxikon (Berkeley, CA) specifically blocks
the mutated form of bRAF (V600E), a mutation that affects
50% of melanoma patients. The ALK inhibitor from
Pfizer (New York), one of approximately 70 such ALK-
directed drugs in preclinical or clinical development,
blocks the function of a receptor tyrosine kinase that is ac-
tivated by chromosomal translocation in about 4% of
NSCLC patients, primarily nonsmokers. In each trial, an
expansion cohort at the MTD accrued patients with tumors
that had the specific mutation in question, and the results
were spectacular. Toxicity, primarily diarrhea and revers-
iblehepatotoxicity,wasmodestandreversible.Ahigherin-
cidenceofcutaneoussquamouscellcancersoftheskinwas
observed in patients treated with the bRAF inhibitor, but
these tumors were easily removed surgically. Although
confirmationoftheseresultsisimportant,thenumberofre-
sponders in the phase I trials is sufficiently impressive to
convince both patients and oncologists that the drugs are
valuable, and even preferable to existing treatments. Appli-
cationsformarketingapprovalarelikelytobecompletedin
the next calendar year, even though the phase II and phase
III trials are just now beginning. The phase II data should
confirm the phase I findings and should be sufficient to al-
low drug registration.
These trials have profound implications for cancer drug
development. They are notable for the speed with which
convincing evidence of drug efficacy was obtained. How-
ever, in expanding the treatment cohort to patients with a
molecular type of tumor, the participation of multiple insti-
tutions was required. Particularly for the ALK trials,
1,000 tumor biopsies from nine institutions worldwide
wereanalyzedfortheEML-4ALKtranslocationtofindthe
10% who received treatment [4]. A second challenge, to
analyze biopsies for the mutations in question, was accom-
plishedthroughcentralresearchlaboratoriesineachstudy,but
rolloutofthesetherapiesforgeneralusewillrequirethateasily
accessible testing be established on a national basis.
This phase I experience has convinced knowledgeable
investigators that tumor profiling and patient selection will
becomearoutinepartofcancerdrugdevelopment.Myown
hospital, the Massachusetts General in Boston, has estab-
lished a tumor profiling laboratory that tests tumor speci-
mens from all new patients with melanoma, NSCLC, colon
cancer, and other tumors of interest, in order to assign pa-
tients to the appropriate clinical trial. A growing number of
cancer centers are establishing such laboratories, because
the capability is essential to performing clinical trials and
will shortly become a necessary technology for routine pa-
tient care [5].
The earlier successes in targeted therapy were derived
from the same rationale for patient selection, but the need
for tumor profiling was not immediately apparent. Imatinib
for chronic myeloid leukemia (CML) won approval after
phase II [6], but patient selection was straightforward be-
cause all CML patients had the mutation in question.
Everyone with CML was a candidate. The clinical
development of trastuzumab depended on the demonstra-
tion of human epidermal growth factor receptor 2/neu am-
plification in tumor specimens, but clinical benefit was less
obvious,withfewresponses,initsphaseItrials[7].Forthis
drug,patientselectionwascomplicatedbyuncertaintiesre-
garding the best method for demonstrating amplification
(immunohistochemistry versus fluorescence in situ hybrid-
ization). The value of trastuzumab was not realized until its
synergy in combination with cytotoxic chemotherapy (pri-
marily taxanes) was demonstrated [8]. The oral epidermal
growth factor receptor (EGFR) inhibitors were developed
in NSCLC patients based on the misguided hypothesis that
expression of EGFR would confer sensitivity. It is now ap-
parent that these small molecules have their greatest activ-
ity against mutant EGFR NSCLC, but this relationship was
established only after phase III trials in unselected patients
were completed [8]. Later phase II–III trials clearly deter-
minedtheresponserate,whichwas70%,inappropriately
selected patients [9].
The development of these new drugs for ALK and
bRAF tumors, even after their anticipated early approval,
has only begun. Like other single agents in cancer treat-
ment, they do not cure the disease. Drug resistance must be
overcome with rationally designed combinations of drugs,
incorporating either other targeted drugs, antibodies, or cy-
totoxics. Understanding mechanisms of resistance should
lead to logical combination trials, and thus it is critical to
obtain tumor biopsies in patients with progressive disease.
Aswassaidmanytimesinthepastregardingcytotoxics,
drug approval is only the first step toward developing ef-
fective therapy. Fortunately, that first step may become a
more rapid process, thanks to patient selection.
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